Skip to main content

2023 |  2022| 2021 | 2020 | 2019 | 2018 | 20172016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | 2004 | 2003 | 2002

Google Scholar Link for Dr. Ainslie  

Google Scholar Link for Dr. Bachelder

2023

    1. Hendy DA, Pena ES, Batty CJ, Ontiveros-Padilla L, III JAR, Dixon TA, Middleton DD, Carlock MA, Ross TM, Bachelder EM, Ainslie KM. COBRA Hemagglutinin and Cgamp Loaded Ace-Dex Microparticles Provide a Broadly Active and Shelf-Stable Influenza Vaccine Platform. Adv. Therap. 2023, 2300273. (link)
    2. Hendy DA, Pena ES, Ontiveros-Padilla L, Dixon TA, Middleton DD, Williamson GL, Lukesh NR, Simpson SS, Stiepel RT, Islam MJ, Carlock MA, Ross TM, Bachelder EM, Ainslie KM. Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations. Bioeng Transl Med. 2023;e10634. (link)
    3. Hendy DA, Lifshits LM, Batty CJ, Carlock MA, Ross TM, Mousa JJ, Bachelder EM, Ainslie KM. Zinc Carnosine Metal-Organic Coordination Polymer as a Potent Broadly Active Influenza Vaccine Platform with In Vitro Shelf-Stability. Mol Pharm. 2023;20(9):4687-97. Epub 20230821. (link)
    4. Stiepel RT, Duggan E, Batty CJ, Ainslie KM. Micro and nanotechnologies: The little formulations that could. Bioeng Transl Med. 2023;8(2):e10421. Epub 20221018.(link)
    5. Pena ES, Lifshits LM, Eckshtain-Levi M, Bachelder EM, Ainslie KM. Metal-organic coordination polymers for delivery of immunomodulatory agents, and infectious disease and cancer vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15(4):e1877. Epub 20230111. (link)
    6. Rose Lukesh N, Middleton DD, Bachelder EM, Ainslie KM. Particle-Based therapies for antigen specific treatment of type 1 diabetes. Int J Pharm. 2023;631:122500. Epub 20221215. (link)
    7. Jasiewicz NE, Mei KC, Oh HM, Chansoria P, Hendy DA, Bonacquisti EE, Bachelder EM, Ainslie KM, Yin H, Qian L, Jensen BC, Nguyen J. ZipperCells Exhibit Enhanced Accumulation and Retention at the Site of Myocardial Infarction. Adv Healthc Mater. 2023;12(4):e2201094. Epub 20221203. (link)
    8. Ontiveros-Padilla L, Batty CJ, Hendy DA, Pena ES, Roque JA, 3rd, Stiepel RT, Carlock MA, Simpson SR, Ross TM, Abraham SN, Staats HF, Bachelder EM, Ainslie KM. Development of a broadly active influenza intranasal vaccine adjuvanted with self-assembled particles composed of mastoparan-7 and CpG. Front Immunol. 2023;14:1103765. Epub 20230324. (link)
    9. Batty CJ, Amouzougan EA, Moore KM, Pena ES, Bachelder EM, Ainslie KM. Humoral Response to Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation. Bioconjugate Chem. 2023. ACS Editors’ Choice (link)
    10. Woodring RN, Gurysh EG, Bachelder EM, Ainslie KM. Drug Delivery Systems for Localized Cancer Combination Therapy. ACS Appl Bio Mater. 2023;6(3):934-50. Epub 2023/02/16. (Invited) (link)
    11. McLaughlin JE, Bachelder JM, Ainslie KM. Distribution of Female and Male First and Last Authorship across Drug Delivery Related Journals with Respect to Year and Journal Impact Factor. Mol Pharm. 2023. Epub 2023/06/23. ACS Editors’ Choice (link)
    12. Mei KC, Stiepel RT, Bonacquisti E, Jasiewicz NE, Chaudhari AP, Tiwade PB, Bachelder EM, Ainslie KM, Fenton OS, Nguyen J. Single-tailed heterocyclic carboxamide lipids for macrophage immune-modulation. Biomater Sci. 2023;11(8):2693-8. Epub 2023/03/31. (link)
    13. Batty CJ, Amouzougan EA, Ross TM, Bachelder EM, Ainslie KM. Sustained delivery of CpG oligodeoxynucleotide by acetalated dextran microparticles augments effector response to Computationally Optimized Broadly Reactive Antigen (COBRA) influenza hemagglutinin. Int J Pharm. 2023 Jan 5;630:122429. (link)
    14. Hendy DA, Haven A, Bachelder EM, Ainslie KM. Preclinical developments in the delivery of protein antigens for vaccination. Expert Opin Drug Deliv. 2023 Feb 2. doi: 10.1080/17425247.2023.2176844. (link)
    15. Batty CJ, Lifshits LM, Hendy DA, Eckshtain-Levi M, Ontiveros-Padilla LA, Carlock MA, Ross TM, Bachelder EM, Ainslie KM. Vinyl Sulfone-functionalized Acetalated Dextran Microparticles as a Subunit Broadly Acting Influenza Vaccine. AAPS J. 2023 Jan 31;25(1):22. doi: 10.1208/s12248-023-00786-6.(link)
    16. Hendy DA, Johnson-Weaver BT, Batty C, Bachelder EM, Abraham SN, Staats HF, Ainslie KM. Delivery of Small Molecule Mast Cell Activators for West Nile Virus Vaccination Using Acetalated Dextran Microparticles. Int J Pharm. 2023 Jan 5;630:122429. doi: 10.1016/j.ijpharm.2022.122429. (link)
    17. Ainslie KM. 9 to 5 in Academia: Addressing Barriers for Women. Mol Pharm. 2023 Jan 2;20(1):1-3. doi: 10.1021/acs.molpharmaceut.2c00899. (link)

2022

    1. Lukesh NR, Middleton DD, Bachelder EM, Ainslie KM. Particle-Based Therapies for Antigen Specific Treatment of Type 1 Diabetes. Int J Pharm. 2022 Dec 15;631:122500.(link)
    2. Varma DM, Batty CJ, Stiepel RT, Graham-Gurysh EG, Roque JA, 3rd, Pena ES, Hasan Zahid MS, Qiu K, Anselmo A, Hill DB, Ross TM, Bachelder EM, Ainslie KM. Development of an Intranasal Gel for the Delivery of a Broadly Acting Subunit Influenza Vaccine. ACS Biomater Sci Eng. 2022;8(4):1573-82.(link)
    3. Salem AK, Nguyen J, Ainslie KM. The AAPS Journal Theme Issue: Rising Stars in Drug Delivery and Novel Carriers. AAPS J. 2022;24(3):51. (link)
    4. Hendy DA, Amouzougan EA, Young IC, Bachelder EM, Ainslie KM. Nano/microparticle Formulations for Universal Influenza Vaccines. AAPS J. 2022;24(1):24. (link)
    5. Gallovic MD, Junkins RD, Sandor AM, Pena ES, Sample CJ, Mason AK, Arwood LC, Sahm RA, Bachelder EM, Ainslie KM, Sempowski GD, Ting JP. STING agonist-containing microparticles improve seasonal influenza vaccine efficacy and durability in ferrets over standard adjuvant. J Control Release. 2022;347:356-68. (link)
    6. Eckshtain-Levi M, Batty CJ, Lifshits LM, McCammitt B, Moore KM, Amouzougan EA, Stiepel RT, Duggan E, Ross TM, Bachelder EM, Ainslie KM. Metal-Organic Coordination Polymer for Delivery of a Subunit Broadly Acting Influenza Vaccine. ACS Appl Mater Interfaces. 2022;14(25):28548-58. (link)
    7. Batty CJ, Gallovic MD, Williams J, Ross TM, Bachelder EM, Ainslie KM. Multiplexed electrospray enables high throughput production of cGAMP microparticles to serve as an adjuvant for a broadly acting influenza vaccine. Int J Pharm. 2022;622:121839. (link)
    8. Stiepel RT, Pena ES, Ehrenzeller SA, Gallovic MD, Lifshits LM, Genito CJ, Bachelder EM, Ainslie KM. A predictive mechanistic model of drug release from surface eroding polymeric nanoparticles. J Control Release. 2022;351:883-95. (link)
    9. Watkins-Schulz R, Batty CJ, Stiepel RT, Schmidt ME, Sandor AM, Chou WC, Ainslie KM, Bachelder EM, Ting JP. Microparticle Delivery of a STING Agonist Enables Indirect Activation of NK Cells by Antigen-Presenting Cells. Mol Pharm. 2022;19(9):3125-38. (link)
    10. Jasiewicz NE, Mei KC, Oh HM, Chansoria P, Hendy DA, Bonacquisti EE, Bachelder EM, Ainslie KM, Yin H, Qian L, Jensen BC, Nguyen J. ZipperCells Exhibit Enhanced Accumulation and Retention at the Site of Myocardial Infarction. Adv Healthc Mater. 2022:e2201094. (link)
    11. McNamara N, Saunders E, Varghese S, Zheng R, Simpson K, Varma DM, Johnson MM, Hasan Zahid MS, Bachelder EM, Ainslie KM, No JH, Koh D, Shum D, Das N, Patra B, Roy J, Talukdar A, Ganguly D, McConville M, Baell J. Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani. Eur J Med Chem. 2022;240:114577. (link)
    12. Stiepel RT, Duggan E, Batty CJ, Ainslie KM. Micro and nanotechnologies: The little formulations that could. Bioengineering & Translational Medicine. e10421 2022. (link)

2021

    1. Pena ES, Graham-Gurysh EG, Bachelder EM, Ainslie KM. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma. International Journal of Molecular Sciences. 2021; 22(23):13160. (Invited) (link)
    2. Genito CJ, Eckshtain-Levi M, Piedra-Quintero ZL, Krovi SA, Kroboth A, Stiepel RT, Guerau-de-Arellano M, Bachelder EM, Ainslie KM. Dexamethasone and Fumaric Acid Ester Conjugate Synergistically Inhibits Inflammation and NF-κB in Macrophages. Bioconjug Chem. 2021 Jun 24. (link)
    3. Zahid MSH, Varma DM, Johnson MM, Landavazo A, Bachelder EM, Blough BE, Ainslie KM. In Vitro Re-sensitization of Resistant Intracellular Salmonella enterica Serovar Typhimurium to Traditional Antibiotics with AR-12. FEMS Microbiol Lett. 2021 Jun 16;368(11):fnab062. (link)
    4. Batty CJ, Bachelder EM, Ainslie KM. Historical Perspective of Clinical Nano and Microparticle Formulations for Delivery of Therapeutics. Trends Mol Med. 2021 Apr 23;S1471-4914(21)00097-6. (link)
    5. Johnson BM, Uchimura T, Gallovic MD, Thamilarasan M, Chou WC, Gibson SA, Deng M, Tam JW, Batty CJ, Williams J, Matsushima GK, Bachelder EM, Ainslie KM, Markovic-Plese S, Ting JP. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways. J Immunol. 2021 May 1;206(9):2015-2028. (link)
    6. Genito CJ, Batty CJ, Bachelder EM, Ainslie KM. Considerations for size, surface charge, polymer degradation, co-delivery, and manufacturability in the development of polymeric particle vaccines for infectious diseases. Advanced NanoBiomed Research. Epub (Invited) (link)
    7. Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine Formulations in Clinical Development for the Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Adv Drug Deliv Rev. 2021 Feb;169:168-189.  (Invited) (link)
    8. Stiepel RT, Batty CJ, MacRaild CA, Norton RS, Bachelder E, Ainslie KM. Merozoite surface protein 2 adsorbed onto acetalated dextran microparticles for malaria vaccination. Int J Pharm. 2021 Jan 25;593:120168.  (link)
    9. Varma DM, Redding EA, Bachelder EM, Ainslie KM. Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis. ACS Biomater Sci Eng. 2021;7(5):1725-41. Epub 2021/05/11. doi: 10.1021/acsbiomaterials.0c01132. (link)
    10. Johnson BM, Uchimura T, Gallovic MD, Thamilarasan M, Chou WC, Gibson SA, Deng M, Tam JW, Batty CJ, Williams J, Matsushima GK, Bachelder EM, Ainslie KM, Markovic-Plese S, Ting JP. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways. J Immunol. 2021;206(9):2015-28. (link)

2020

    1. Varma DM, Redding EA, EM Bachelder, Ainslie KM. Nano-and Microformulations to Advance Therapies for Visceral Leishmaniasis ACS Biomaterials Science & Engineering. 2020 Online Oct 16. (Invited) (link)
    2. Moore KM, Murthy AB, Graham-Gurysh EG, Hingtgen SD, Bachelder EM, Ainslie KM. Polymeric Biomaterial Scaffolds for Tumoricidal Stem Cell Glioblastoma Therapy. ACS Biomaterials Science & Engineering. 2020;6(7):3762-77. (link)
    3. Moore KM, Batty CJ, Stiepel RT, Genito CJ, Bachelder EM, Ainslie KM. Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications. ACS Appl Mater Interfaces. 2020 Aug 24. (link)
    4. Varma DM, Zahid MSH, Bachelder EM, Ainslie KM. Formulation of host-targeted therapeutics against bacterial infections. Transl Res. 2020 Mar 16:S1931-5244(20)30046-3. (link)
    5. Iweala OI, Choudhary SK, Addison CT, Batty CJ, Kapita CM, Amelio C, Schuyler AJ, Deng S, Bachelder EM, Ainslie KM, Savage PB, Brennan PJ, Commins SP. Glycolipid-mediated basophil activation in alpha-gal allergy. J Allergy Clin Immunol. 2020 Feb 20:S0091-6749(20)30258-X. (link)
    6. Graham-Gurysh EG, Murthy AB, Moore KM, Hingtgen SD, Bachelder EM, Ainslie KM. Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy. J Control Release. 2020 Apr 23;323:282-292. (link)
    7. Graham-Gurysh EG, Moore KM, Schorzman AN, Lee T, Zamboni WC, Hingtgen SD, Bachelder EM, Ainslie KM. Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma. ACS Appl Mater Interfaces. 2020 Apr 29;12(17):19345-19356. (link)
    8. Moore KM, Graham-Gurysh EG, Bomba HN, Murthy AB, Bachelder EM, Hingtgen SD, Ainslie KM. Impact of composite scaffold degradation rate on neural stem cell persistence in the glioblastoma surgical resection cavity. Mater Sci Eng C Mater Biol Appl. 2020 Jun;111:110846. doi: 10.1016/j.msec.2020.110846. Epub 2020 Mar 13. (link)

2019

    1. Zahid MSH, Johnson MM, Tokarski RJ, 2nd, Satoskar AR, Fuchs JR, Bachelder EM, Ainslie KM. Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani. Int J Parasitol Drugs Drug Resist. 2019;10:125-32. (link)
    2. Steipel RT, Gallovic MD, Batty CJ, Bachelder EM, Ainslie KM. Electrospray for generation of drug delivery and vaccine particles applied in vitro and in vivo. Materials Science and Engineering: C. 2019;105:110070. (link)
    3. Watkins-Schulz R, Tiet P, Gallovic MD, Junkins RD, Batty C, Bachelder EM, Ainslie KM, Ting JPY. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8(+) T cell-mediated anti-tumor immunity. Biomaterials. 2019;205:94-105. (link)
    4. Pradhan S, Moore KM, Ainslie KM, Yadavalli VK. Flexible, microstructured surfaces using chitin-derived biopolymers. J Mater Chem B. 2019;7(35):5328-35. (link)

2018

    1. Junkins RD, Gallovic MD, Johnson BM, Collier MA, Watkins-Schulz R, Cheng N, David CN, McGee CE, Sempowski GD, Shterev I, McKinnon K, Bachelder EM, Ainslie KM, Ting JP. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release. 2018;270:1-13. (link)
    2. Cheng N, Watkins-Schulz R, Junkins RD, David CN, Johnson BM, Montgomery SA, Peine KJ, Darr DB, Yuan H, McKinnon KP, Liu Q, Miao L, Huang L, Bachelder EM, Ainslie KM, Ting JP. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight. 2018;3(22). (link)
    3. Krovi SA, Gallovic MD, Keller AM, Bhat M, Tiet P, Chen N, Collier MA, Gurysh EG, Pino EN, Johnson MM, Zahid MSH Cottrell ML, Pirone JR, Kashuba AD, Kwiek JJ, Bachelder EM, Ainslie KM. Injectable Long-acting Human Immunodeficiency Virus Antiretroviral Prodrugs with Improved Pharmacokinetic Profiles. Int J Pharm. (link)
    4. Chen N, Gallovic MD, Tiet P, McGee CE, Sempowski GD, Ting JPY, Ainslie KM, Bachelder EM. Degradation of Acetalated Dextran Microparticles to Optimize M2e-Based Universal Influenza Vaccine Efficacy. JCR ePub 2018. (link)
    5. Batty CJ, Tiet P, Bachelder EM, Ainslie KM. Drug Delivery for Cancer Immunotherapy and Vaccines. Pharm Nanotechnol. 2018 Sep 18. (link)
    6. Collier MA, Junkins R, Gallovic MD, Johnson B, Johnson MM, Macintyre A, Sempowski G, Bachelder EM, Ting JPY, Ainslie KM. Acetalated Dextran microparticles for co-delivery of STING and TLR7/8 agonists. Mol Pharm. (link)
    7. Johnson MM, Collier MA, Hoang KV, Pino EN, Gurysh EG, Gallovic MD, Zahid MS, Chen N, Schlesinger LS, Gunn JS, Bachelder EM, Ainslie KM. In vivo and Cellular Trafficking of Acetalated Dextran Microparticles for Delivery of a Host-Directed Therapy for Salmonella enterica Serovar Typhi Infection. Mol Pharm. (link)
    8. Chen N, Kroger CJ, Tisch RM, Bachelder EM, Ainslie KM. Prevention of Type 1 Diabetes with Acetalated Dextran Microparticles Containing Rapamycin and Pancreatic Peptide P31. Adv Healthc Mater. 2018 Jul 26:e1800341. (link)
    9. Jongwattanapisan P, Terajima M, Miguez PA, Querido W, Nagaoka H, Sumida N, Gurysh EG, Ainslie KM, Pleshko N, Perera L, Yamauchi M. Identification of the effector domain of biglycan that facilitates BMP-2 osteogenic function. Sci Rep. 2018 May 4;8(1):7022.  (link)
    10. Graham-Gurysh E, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR, Hingtgen SD, Ainslie KM. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Mol Pharm. 2018;15(3):1309-18. (link)
    11. Chen N, Johnson MM, Collier MA, Gallovic MD, Bachelder EM, Ainslie KM. Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses. J Control Release. 2018;273:147-59. (link)

2017

    1. Junkins R, Gallovic M, Johnson B, Collier M, Watkins-Schulz R, Cheng N, David C, McGee C, Sempowski G, Shterev I, McKinnone K, Bachelder E, Ainslie K, Ting J. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. Journal of Controlled Release. 2017; 21(270):1-13. (link)
    2. Webb LM, Amici SA, Jablonski KA, Savardekar H, Panfil AR, Li L, Zhou W, Peine K, Karkhanis V, Bachelder EM, Ainslie KM, Green PL, Li C, Baiocchi RA, Guerau-de-Arellano M. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. J Immunol. 2017;198(4):1439-1451. (link)
    3. Peine KJ, Chen N, Bachelder EM, Ainslie KM. Drug Delivery Strategies for Tolergenic Therapy For Autoimmune Dieases in an Antigen Specific Manner. In: Keservani R, editor. Recent Advances in Drug Delivery Technology. Hershey, PA: IGI Global; 2017.
    4. Johnson MM, Ainslie KM. Vaccines for the Prevention of Melioidosis and Glanders. Current Tropical Medicine Reports. 2017;4(3):136.
    5. Gallovic MD, Bachelder EM, Ainslie KM. Immunostimulatory Inulin Adjuvants in Prophylactic Vaccines Against Pathogens. In: Davis CR, editor. Inulin: Chemical Properties, Uses and Health Benefits: Nova Science Publishers; 2017.
    6. Collier MA, Bachelder EM, Ainslie KM. Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production. Pharm Res. 2017;34(2):419-426. (link)
    7. Chen N, Peine K, Collier M, Gautam S, Jablonski K, Guerau-de-Arellano M, Ainslie K, Bachelder E. Co-Delivery of Disease Associated Peptide and Rapamycin via Acetalated Dextran Microparticles for Treatment of Multiple Sclerosis. Advanced Biosystems. 2017. (link)
    8. Bachelder EM, Pino EN, Ainslie KM. Acetalated Dextran: A Tunable and Acid-Labile Biopolymer with Facile Synthesis and a Range of Applications. Chem Rev. 2017;117(3):1915-1926. (link)

2016

    1. Gallovic MD, Schully KL, Bell MG, Elberson MA, Palmer JR, Darko CA, Bachelder EM, Wyslouzil BE, Keane-Myers AM, Ainslie KM. Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure. Adv Healthc Mater. 2016. (link)
    2. Chen N, Collier MA, Gallovic MD, Collins GC, Sanchez CC, Fernandes EQ, Bachelder EM, Ainslie KM. Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight. Int J Pharm. 2016;512(1):147-157. (link)
    3. Gallovic MD, Bandyopadhyay S, Borteh H, Montjoy DG, Collier MA, Peine KJ, Wyslouzil BE,  Bachelder EM, Ainslie KM. Microparticles formulated from a family of novel silylated polysaccharides demonstrate inherent immunostimulatory properties and tunable hydrolytic degradability. J. Mater. Chem. B, 2016. (link)
    4. Collier MA, Gallovic MD, Bachelder EM, Sykes CD, Kashuba A, Ainslie KM. Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable. Pharm Res. 2016 May 6. (link)
    5. Duong AD, Collier MA, Bachelder EM, Wyslouzil BE, Ainslie KM. One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading. Mol Pharm. 2016 Jan 4;13(1):92-9. (link)
    6. Hoang KV, Curry H, Collier MA, Borteh H, Bachelder E, Schlesinger LS, Gunn JS, Ainslie K. Needle-free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge. Antimicrob Agents Chemother. 2016 Jan 19. (link)
    7. Gallovic MD, Montjoy DG, Collier MA, Do C, Wyslouzil BE, Bachelder EM, Ainslie KM. Chemically modified inulin microparticles serving dual function as a protein antigen delivery vehicle and immunostimulatory adjuvant. Biomater Sci. 2016 Feb 23;4(3):483-93. (link)
    8. Collier MA, Peine KJ, Gautam S, Oghumu S, Varikuti S, Borteh H, Papenfuss TL, Sataoskar AR, Bachelder EM, Ainslie KM. Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles. Int J Pharm. 2016 Feb 29;499(1-2):186-94. (link)

2015

    1. Schully KL, Bell MG, Prouty AM, Gallovic MD, Gautam S, Peine KJ, Sharma S, Bachelder EM, Pesce JT, Elberson MA, Ainslie KM, Keane-Myers A. Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis. Int J Pharm. 2015 Nov 30;495(2):849-61. (link)
    2. Chen N, Peine KJ, Bachelder EM, Ainslie KM. Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases. Pharmaceutical Nanotechnology, 2015 3(2): 85-100 (link)
    3. Gupta G, Peine KJ, Abdelhamid D, Snider H, Shelton AB, Rao, Kotha SR, Huntsman HC, Varikuti S, Oghumu S, Naman CB, Pan L, Parinandi NL, Papenfuss TL, Kinghorn AD, Bachelder EM, Ainslie KM, Fuchs JR,  Satoskar AR. A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani. ACS Infectious Diseases 2015 1 (10), 497-506. (link)

2014

    1. Hoang KV, Borteh HM, Rajaram MV, Peine KJ, Curry H, Collier MA, Homsy ML, Bachelder EM, Gunn JS, Schlesinger LS, Ainslie KM. Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection. Int J Pharm. 2014 Dec 30;477(1-2):334-43. (link)
    2. Peine KJ, Guerau-de-Arellano M, Lee P, Kanthamneni N, Severin M, Probst GD, Peng H, Yang Y, Vangundy Z, Papenfuss TL, Lovett-Racke AE, Bachelder EM, Ainslie KM.Treatment of Experimental Autoimmune Encephalomyelitis by Codelivery of Disease Associated Peptide and Dexamethasone in Acetalated Dextran Microparticles. Mol Pharm. 2014 (link)
    3. Peine KJ, Gupta G, Brackman DJ, Papenfuss TL, Ainslie KM, Satoskar AR, Bachelder EM. Liposomal resiquimod for the treatment of Leishmania donovani infection. J Antimicrob Chemother. 2014 Jan;69(1):168-75 (link)

2013

    1. Collier MA, Gallovic MD, Peine KJ, Duong AD, Bachelder EM, Gunn JS, Schlesinger LS, Ainslie KM. Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Rev Anti Infect Ther. 2013 Nov;11(11):1225-35. (link)
    2. Peine KJ, Bachelder EM, Vangundy Z, Papenfuss T, Brackman DJ, Gallovic MD, Schully K, Pesce J, Keane-Myers A, Ainslie KM. Efficient delivery of the toll-like receptor agonists polyinosinic:polycytidylic acid and CpG to macrophages by acetalated dextran microparticles. Mol Pharm. 2013 Aug 5;10(8):2849-57. (link)
    3. Borteh HM, Gallovic MD, Sharma S, Peine KJ, Miao S, Brackman DJ, Gregg K, Xu Y, Guo X, Guan J, Bachelder EM, Ainslie KM. Electrospun acetalated dextran scaffolds for temporal release of therapeutics. Langmuir. 2013 Jun 25;29(25):7957-65. (link)
    4. Schully KL, Sharma S, Peine KJ, Pesce J, Elberson MA, Fonseca ME, Prouty AM, Bell MG, Borteh H, Gallovic M, Bachelder EM, Keane-Myers A, Ainslie KM. Rapid Vaccination Using an Acetalated Dextran Microparticulate Subunit Vaccine Confers Protection Against Triplicate Challenge by Bacillus Anthracis. Pharm Res, 2013(link)
    5. Duong AD, Sharma S, Peine KJ, Gupta G, Satoskar AR, Bachelder EM, Wyslouzil BE, Ainslie KM. Electrospray Encapsulation of Toll-Like Receptor Agonist Resiquimod in Polymer Microparticles for the Treatment of Visceral Leishmaniasis. Mol Pharm, 2013 (link)

2012

    1. Kauffman KJ, Do C, Sharma S, Gallovic MD, Bachelder EM, Ainslie KM. Synthesis and characterization of acetalated dextran polymer and microparticles with ethanol as a degradation product. ACS Appl Mater Interfaces. 2012 Aug 22;4(8):4149-55 (link)
    2. Kanthamneni N, Sharma S, Meenach SA, Billet B, Zhao Ji-Cheng, Bachelder EM, Ainslie KM. Enhanced stability of horseradish peroxidase encapsulated in acetalated dextran microparticles stored outside cold chain condition. Int J Pharm. 2012 Jul 15;431(1-2):101-10. (link)
    3. Meenach SA, Kim YJ, Kauffman KJ, Kanthamneni N, Bachelder EM, Ainslie KM. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Mol Pharm. 2012 Feb 6;9(2):290-8. (link)
    4. Kauffman KJ, Kanthamneni N, Meenach SA, Pierson BC, Bachelder EM, Ainslie KM. Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. Int J Pharm. 2012 Jan 17;422(1-2):356-63. (link)

2011

    1. Saldanha KJ, Doan RP, Ainslie KM, Desai TA, Majumdar S. Micrometer-sized iron oxide particle labeling of mesenchymal stem cells for magnetic resonance imaging-based monitoring of cartilage tissue engineering. Magn Reson Imaging. 2011 Jan;29(1):40-9.(link)

2010

    1. Bachelder EM, Beaudette TT, Broaders KE, Fréchet JM, Albrecht MT, Mateczun AJ, Ainslie KM, Pesce JT, Keane-Myers AM. In Vitro Analysis of Acetalated Dextran Microparticles as a Potent Delivery Platform for Vaccine Adjuvants. Mol Pharm. 2010 Apr 1. (link)
    2. Ainslie KM, Thakar RT, Bernards DA, Desai TA.  Nanotechnology in Tissue Engineering and Regenerative Medicine (Chapter: Inflammation Response to Implanted Nanostructured Materials) CRC/Taylor and Francis, New York (2010). (link)
    3. Ayala P, Bernards DA, Thakar RT, Ainslie KM, Desai TA.  The Handbook of Enabling Technologies for Regenerative Medicine (Chapter: Fabrication of cell mircrointegrated tissues) CRC/Taylor and Francis, New York (2010).

2009

    1. Ainslie KM, Beaudette TT, Petty L, Bachelder EM, and Desai TA.
      Microfabricated Devices for Enhanced Bioadhesive Drug Delivery:
      Attachment to and Small Molecule Release through a Cell Monolayer under
      Flow. Small Small. 2009 Dec;5(24):2857-63. (link)
    2. Beaudette TT, Cohen JA, Bachelder EM, Broaders KE, Cohen JL, Engleman EG, Fréchet JM.Chemoselective Ligation in the Functionalization of Polysaccharide-Based Particles.J Am Chem Soc. 2009 Jul 10.(link)
    3. Beaudette T, Bachelder E, Cohen J, Obermeyer A, Broaders K, Frechet JM, Kang E, Mende I, Tseng WW, Davidson M, and Engleman EG. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm 2009. (link)
    4. Broaders KE, Cohen JA, Beaudette TT, Bachelder EM, and Frechet JM. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc Natl Acad Sci U S A 106: 5497-5502, 2009. (link)
    5. Cohen JA, Beaudette TT, Tseng WW, Bachelder EM, Mende I, Engleman EG, and Frechet JM. T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size. Bioconjug Chem 20: 111-119, 2009. (link)
    6. Ainslie KM, Tao SL, Popat KC, Daniels H, Hardev V, Grimes CA, and Desai TA. In vitro inflammatory response of nanostructured titania, silicon oxide, and polycaprolactone. J Biomed Mater Res A 2009 Dec;91(3):647-55. (link)
    7. Ainslie KM, Thakar RT, Bernards DA, Desai TA. Biological Interactions on Materials Surfaces: Understanding and Controlling Protein, Cell and Tissue Responses (Chapter: Inflammation Response to Implanted Nanostructured Materials) Elsevier, New York (2009). (link)

2008

    1. Ainslie KM, and Desai TA. Microfabricated Implants for Applications in Therapeutic Delivery, Tissue Engineering, and Biosensing. Lab Chip 8:1864-78, 2008.(link)
    2. Ainslie KM, Kraning CM, and Desai TA. Microfabrication of an asymmetric, multi-layered microdevice for controlled release of orally delivered therapeutics. Lab Chip 8: 1042-1047, 2008. (link)
    3. Ainslie KM, Tao SL, Popat KC, and Desai TA. In vitro immunogenicity of silicon-based micro- and nanostructured surfaces. ACS Nano 2: 1076-1084, 2008. (link)
    4. Bachelder EM, Beaudette TT, Broaders KE, Dashe J, and Frechet JM. Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications. J Am Chem Soc 130: 10494-10495, 2008. (link)
    5. Bachelder EM, Beaudette TT, Broaders KE, Paramonov SE, Dashe J, and Frechet JM.
      Acid-degradable polyurethane particles for protein-based vaccines:
      biological evaluation and in vitro analysis of particle degradation
      products. Mol Pharm 5: 876-884, 2008. (link)
    6. Paramonov SE, Bachelder EM, Beaudette TT, Standley SM, Lee CC, Dashe J, and Frechet JM. Fully acid-degradable biocompatible polyacetal microparticles for drug delivery. Bioconjug Chem 19: 911-919, 2008. (link)
    7. Saldanha KJ, Piper SL, Ainslie KM, Kim HT, and Majumdar S.
      Magnetic resonance imaging of iron oxide labelled stem cells:
      applications to tissue engineering based regeneration of the
      intervertebral disc. Eur Cell Mater 16: 17-25, 2008. (link)

2007

    1. Ainslie KM, Bachelder EM, Borkar S, Zahr AS, Sen A, Badding JV, and Pishko MV. Cell adhesion on nanofibrous polytetrafluoroethylene (nPTFE). Langmuir 23: 747-754, 2007. (link)
    2. Ainslie KM, Bachelder EM, Sharma G, Grimes C, and Pishko MV. Macrophage Cell Adhesion and Inflammation Cytokines on Magnetostrictive Nanowires. Nanotoxicology 1: 279 – 290, 2007.
    3. Dyer MA, Ainslie KM, and Pishko MV. Protein adhesion on silicon-supported hyperbranched poly(ethylene glycol) and poly(allylamine) thin films. Langmuir 23: 7018-7023, 2007. (link)
    4. Lee KS, Scanga CA, Bachelder EM, Chen Q, and Snapper CM.
      TLR2 synergizes with both TLR4 and TLR9 for induction of the
      MyD88-dependent splenic cytokine and chemokine response to
      Streptococcus pneumoniae. Cell Immunol 245: 103-110, 2007. (link)
    5. Stine R, Cole CL, Ainslie KM, Mulvaney SP, and Whitman LJ. Formation of primary amines on silicon nitride surfaces: a direct, plasma-based pathway to functionalization. Langmuir 23: 4400-4404, 2007. (link)

2005

    1. Ainslie KM, Sharma G, Dyer MA, Grimes CA, and Pishko MV. Attenuation of protein adsorption on static and oscillating magnetostrictive nanowires. Nano Letters 5: 1852-1856, 2005. (link)
    2. Bachelder EM, Ainslie KM, and Pishko MV. Utilizing a quartz crystal microbalance for quantifying CD4(+) T cell counts. Sensor Letters 3: 211-215, 2005. (.pdf)
    3. Ainslie KM, Garanich JS, Dull RO, and Tarbell JM. Vascular smooth muscle cell glycocalyx influences shear stress-mediated contractile response. J Appl Physiol 98: 242-249, 2005. (link)

2004

    1. Ainslie K, Shi ZD, Garanich JS, and Tarbell JM. Rat aortic smooth muscle cells contract in response to serum and its components in a calcium independent manner. Annals of Biomedical Engineering 32: 1667-1675, 2004. (link)
    2. Alpan O, Bachelder E, Isil E, Arnheiter H, and Matzinger P. ‘Educated’ dendritic cells act as messengers from memory to naive T helper cells. Nat Immunol 5: 615-622, 2004. (link)

2003

    1. Florian JA, Kosky JR, Ainslie K, Pang ZY, Dull RO, and Tarbell JM. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circulation Research 93: E136-E142, 2003. (link)

2002

    1. Civelek M, Ainslie K, Garanich JS, and Tarbell JM. Smooth muscle cells contract in response to fluid flow via a Ca2+-independent signaling mechanism. J Appl Physiol 93: 1907-1917, 2002. (link)
    2. Sharma R, Yellowley CE, Civelek M, Ainslie K, Hodgson L, Tarbell JM, and Donahue HJ. Intracellular calcium changes in rat aortic smooth muscle cells in response to fluid flow. Ann Biomed Eng 30: 371-378, 2002. (link)